Trial Profile
A Phase IIa Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs TAS 303 (Primary)
- Indications Stress incontinence
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 28 Jan 2019 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
- 03 Aug 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.